Novo Nordisk downgraded by leading banks as CagriSema trial flops against Zepbound

Core Viewpoint - Novo Nordisk's CagriSema obesity drug failed to demonstrate non-inferior weight loss compared to Eli Lilly's Zepbound, leading to significant downgrades from analysts and a reassessment of the company's long-term earnings potential [1][2]. Group 1: Trial Results and Implications - The REDEFINE-4 phase III trial, which lasted 84 weeks, did not yield favorable results for CagriSema, despite the extended duration intended to provide an advantage [3]. - The complexity of CagriSema's dual-chamber delivery device poses manufacturing challenges compared to Zepbound's simpler formulation, further diminishing its competitive edge [4]. - The trial results indicated not only inferior weight loss but also limited effectiveness in blood glucose control, reducing CagriSema's appeal in both obesity and diabetes markets [5]. Group 2: Analyst Reactions and Market Impact - Deutsche Bank downgraded Novo Nordisk from 'buy' to 'hold', reducing its price target by 31% from DKK400 to DKK275, citing a significant blow to their optimistic outlook on CagriSema [2]. - JPMorgan also downgraded the stock to 'neutral', setting a new price target of DKK250, concluding that the drug's commercial potential is materially impaired [2]. - The failure of CagriSema raises concerns about Novo Nordisk's future in the obesity and diabetes markets, especially as the patent for semaglutide is set to expire at the end of 2031 [6].